🔗 Share this article

Given that America undertakes unprecedented changes to its immunization recommendations, a particular individual has surfaced somewhat surprisingly: Tracy Beth Høeg, a US-based sports physician and epidemiologist who initially gained attention by questioning COVID-19 vaccinations in the global health crisis and has zeroed in on possible deaths following Covid immunization in her recent tenure at the FDA.

Scheduled Changes to Pediatric Vaccine Schedule

Public health authorities planned to announce sweeping revisions to the childhood immunization program recently, aligning the US with Denmark’s vaccine program, sources say – a major change that would put the US out of step with much of the global community with no evidence for improved outcomes. The announcement has been pushed back until the coming year.

Instead of the top vaccines chief, Tracy Beth Høeg is scheduled to address the audience at the meeting. She was just designated acting director of the FDA’s drug evaluation center, the fifth appointee to head the office this year.

A Shift at the Regulatory Body

This interim role could signify a tighter collaboration between the drug and vaccine branches as Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a greater focus upon reevaluating previously authorized immunizations at the FDA.

The new acting director has often pushed for discontinuing some childhood shot schedules in the US to become more like Denmark's approach, a country with nationalized medicine and a population roughly the size of the state of Wisconsin.

So far statements, she has kept her attention on vaccination policy – typically the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Qualifications

Dr. Høeg has no obvious experience in pharmaceutical research, regulation or administrative roles, which has been typical for former heads of the biologics center. She has served at the FDA as a key advisor to the agency head and CBER since March.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in leading a major agency. She has no expertise in industry regulation.”

Past directors of the center would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, noted Janet Woodcock. “Clearly, she has not acquired the kind of background that prior appointees who led CBER have had.”

This division has an enormous range of responsibilities at the agency, Woodcock stated.

“Everybody just zeroes in on the innovative therapies, but the generic drug division authorizes a multitude of generic medications. There is also a biosimilars division, over-the-counter program and other areas, and all of those must be supervised,” Dr. Woodcock noted. “The responsibility you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a major administrative element to the job, which oversees over 5,000 employees. “It is a huge administrative position, if you execute it properly,” the former official said.

Response and Disputed Initiatives

In response to questions about Dr. Høeg's qualifications and whether this selection signifies greater collaboration among regulatory chiefs on vaccines, a press secretary said that the “concerns are based on inaccurate assumptions”.

“Her resume aligns with the duties of her role,” the spokesperson said, pointing to the period Høeg spent advising the FDA commissioner on “medication safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a controversial rapid medication authorization process that reportedly troubled her former heads. “How are these drugs being picked for this fast-track system? Who takes the calls?” Howard asked. “There is a lot of lack of transparency going on at the FDA right now.”

Broadly speaking, he said, “the Food and Drug Administration looks to be trending towards laxer rules of pharmaceuticals, aside from vaccines.”

Public Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if concerning, track record, critics said. She released a study using non-validated public submissions to determine the rate of heart inflammation following Covid immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccinations are pose a greater threat than they are.

Among her “desired changes” for the new government included revising guidelines for new vaccines and discontinuing “optional” immunizations, she remarked after the election on a online show. At the FDA, Høeg has allegedly proposed barring adolescent males from getting COVID-19 vaccinations.

“She is an complete ideologue who begins with her conclusions and tailors the evidence to fit the science in a highly disingenuous, untruthful manner,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of other dissenters, {like|